|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: GLOBOCAN 2008 v1.2, Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 10 (Internet).
International Agency for Research on Cancer; Lyon, France: pp.
2010http://globocan.iarc.fr.
Accessed March 15, 2012.
|
|
2
|
Brown LM and Devesa SS: Epidemiologic
trends in esophagealand gastric cancer in the United States. Surg
Oncol Clin N Am. 11:235–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 4:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
MacLachlan TK, Sang N and Giordano A:
Cyclins, cyclin-dependent kinases and cdk inhibitors: implications
in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr.
5:127–156. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zafonte BT, Hulit J, Amanatullah DF,
Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP and
Pestell RG: Cell-cycle dysregulation in breast cancer therapies
targeting the cell cycle. Front Biosci. 5:938–961. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sedlacek HH: Mechanisms of action of
flavopiridol. Crit Rev Oncol Hematol. 38:139–170. 2001. View Article : Google Scholar
|
|
7
|
Monga M and Sausville EA: Developmental
therapeutics program at the NCI: molecular target and drug
discovery process. Leukemia. 16:520–526. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Senderowicz AM and Sausville: Preclinical
and clinical development of cyclin-dependent kinase modulators. J
Natl Cancer Inst. 92:376–387. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaur G, Stetler-Stevenson M, Sebers S,
Worland P, Sedlacek H, Myers C, Czech J, Naik R and Sausville E:
Growth inhibition with reversible cell cycle arrest of carcinoma
cells by flavone L86-8275. JNCI J Natl Cancer Inst. 84:1736–1740.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Camphausen K, Brady K, Burgan W, Carra M,
Russell J, Bull E and Tofilon P: Flavopiridol enhances human tumor
cell radio-sensitivity and prolongs expression of gammaH2AX foci.
Mol Cancer Ther. 3:409–416. 2004.PubMed/NCBI
|
|
11
|
Byrd JC, Shinn C, Waselenko JK, Fuchs EJ,
Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E and Grever
MR: Flavopiridol induces apoptosis in chronic lymphocytic leukemia
cells via activation of caspase-3 without evidence of bcl-2
modulation or dependence on functional p53. Blood. 92:3804–3816.
2008.PubMed/NCBI
|
|
12
|
Patel V, Senderowicz AM, Pinto D, Igishi
T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA and
Gutkind JS: Flavopiridol, a novel cyclin-dependent kinase
inhibitor, suppresses the growth of head and neck squamous cell
carcinomas by inducing apoptosis. J Clin Invest. 102:1674–1681.
1998. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Bhuiyan M and Sarkar FH: Induction
of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by
genistein. Int J Oncol. 15:525–533. 1999.PubMed/NCBI
|
|
14
|
Fredersdorf S, Burns J, Milne AM, Packham
G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM,
Barnes DM, Shousha S, O’Hare MJ and Lu X: High level expression of
p27kip1 and cyclin D1 in some human breast cancer cells: Inverse
correlation between the expression of p27kip1 and degree of
malignancy in human breast and colorectal cancers. Proc Natl Acad
Sci USA. 94:6380–6385. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gansauge S, Gansauge F, Ramadani M, Stobbe
H, Rau B, Harada N and Beger HG: Overexpression of cyclin D1 in
human pancreatic carcinoma is associated with poor prognosis.
Cancer Res. 57:1634–1637. 1997.PubMed/NCBI
|
|
16
|
Adélaide J, Monges G, Dérdérian C, Seitz
JF and Birnbaum D: Esophageal cancer and amplification of the human
cyclin D gene CCND1/PRAD1. Br J Cancer. 71:64–68. 1995.PubMed/NCBI
|
|
17
|
Blagosklonny MV and Pardee AB: The
restriction point of the cell cycle. Cell Cycle. 1:103–110. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Filmus J, Robles AI, Shi W, et al:
Induction of cyclin D1 overexpression by activated ras. Oncogene.
9:3627–3633. 1994.PubMed/NCBI
|
|
19
|
Aktas H, Cai H and Cooper GM: Ras links
growth factor signaling to the cell cycle machinery via regulation
of cyclin D1 and the cdk inhibitor p27KIP1. Mol Cell Biol.
17:3850–3857. 1997.PubMed/NCBI
|
|
20
|
Winston JT, Coats SR, Wang YZ and Pledger
WJ: Regulation of the cell cycle machinery by oncogenic ras.
Oncogene. 12:127–134. 1996.PubMed/NCBI
|
|
21
|
Chang HY and Yang X: Proteases for cell
suicide: functions and regulation of caspases. Microbiol Mol Biol
Rev. 64:821–846. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
